ImmuXell Biotech Co., Ltd, a Shanghai-based cell therapy developer, has reportedly secured over RMB 100 million (USD 13.7 million) in a Series A financing round. The round was led by SDIC Venture Capital, with significant participation from Huangpu Pharmaceutical Fund and Yuanxi Haihe Fund. The funds will be instrumental in advancing the regulatory clinical studies for ImmuXell’s innovative KRAS G12V mutation-targeted TCR-T cell therapy, as well as supporting pipeline product development and fostering international cooperation.
Investor Support and Strategic Goals
The Series A financing round reflects the confidence of leading investors in ImmuXell’s potential to revolutionize cell therapy. The proceeds will be directed towards bolstering the company’s ongoing clinical studies, particularly for its KRAS-targeted TCR-T cell therapy, which has already concluded an investigator-initiated trial (ITT) in advanced pancreatic ductal adenocarcinoma. This investment will also support the development of additional pipeline candidates, including a TCR-NK-targeted product and a TCR fusion protein candidate.
Company Background and Pipeline
Founded in 2021, ImmuXell Bio has quickly established itself as a leader in the field of cell therapy, boasting a robust in-house product pipeline. The company’s lead candidate, the KRAS-targeted TCR-T cell therapy, represents a significant advancement in the treatment of cancers driven by the KRAS G12V mutation. ImmuXell’s commitment to innovation and its strategic approach to product development position it at the forefront of the biotech industry.-Fineline Info & Tech
